透析システム
- 专利权人:
- 三菱レイヨン・クリンスイ株式会社
- 发明人:
- 寺田 雄之,佐藤 仁一,藤原 博,桜庭 克典,森本 真夫,鴨下 洋一,平川 克昭
- 申请号:
- JP2009133096
- 公开号:
- JP5425527B2
- 申请日:
- 2009.06.02
- 申请国别(地区):
- JP
- 年份:
- 2014
- 代理人:
- 摘要:
PROBLEM TO BE SOLVED: To provide a dialysis system capable of subjecting a purified water producing device and a dialyzer to a hot-water treatment with heated purified water by operatively connecting the purified water producing device and dialyzer by signal transmission/reception, and capable of preventing the purified water heated by a dialysis solution from being mixed in dialysis solution because of false operation, etc. during the hot-water treatment.
SOLUTION: The dialysis system includes the purified water producing device 10 and the dialyzer 20. The dialysis system has the following functions: a function of transmitting a hot-water treatment signal (a1) after confirmation of prescribed matters after receiving a treatment requesting signal (b2), and outputting an alarm and/or leaving a history if the hot-water treatment signal (a2) is not transmitted within a prescribed period of time a function of cooling the purified water within the purified water producing device 10 just after the treatment requesting signal (b2) is stopped or a purified water requesting signal (b1) is received within a prescribed hot-water treatment time and a function of controlling the temperature of drain water when the treatment requesting signal (b2) is stopped.
COPYRIGHT: (C)2011,JPO&INPIT
- 来源网站:
- 中国工程科技知识中心
相关发明人
相关专利
- COMPOSITION FOR ADMINISTRATION OF BIOLOGICALLY ACTIVE PRINCIPLES IN GINECOLOGICAL AND RETAL SCOPE, AND USES FOR THE SAME.
- ADMINISTRATION DE PROMÉDICAMENTS ACTIVÉS PAR L'HYPOXIE EN COMBINAISON À DES INHIBITEURS DE CHK1 POUR LE TRAITEMENT DU CANCER
- ADMINISTRATION DE PROMÉDICAMENTS ACTIVÉS PAR L'HYPOXIE EN COMBINAISON À DES INHIBITEURS DE CHK1 POUR LE TRAITEMENT DU CANCER
- ADMINISTRATION DE PROMÉDICAMENTS ACTIVÉS PAR L'HYPOXIE EN COMBINAISON À DES INHIBITEURS DE CHK1 POUR LE TRAITEMENT DU CANCER
- ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR TREATING CANCER